Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

NCT01909934 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Brentuximab vedotin

Sponsor

Takeda

Collaborators

[object Object]